SELLAS Life Sciences Group Inc (SLS) concluded trading on Thursday at a closing price of $2.03, with 5.23 million shares of worth about $10.62 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 128.60% during that period and on June 26, 2025 the price saw a gain of about 9.73%. Currently the company’s common shares owned by public are about 99.78M shares, out of which, 97.67M shares are available for trading.
Stock saw a price change of 29.30% in past 5 days and over the past one month there was a price change of 5.18%. Year-to-date (YTD), SLS shares are showing a performance of 67.77% which increased to 95.19% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.77 but also hit the highest price of $2.12 during that period. The average intraday trading volume for SELLAS Life Sciences Group Inc shares is 2.23 million. The stock is currently trading 22.88% above its 20-day simple moving average (SMA20), while that difference is up 26.68% for SMA50 and it goes to 58.98% higher than SMA200.
SELLAS Life Sciences Group Inc (NASDAQ: SLS) currently have 99.78M outstanding shares and institutions hold larger chunk of about 14.33% of that.
The stock has a current market capitalization of $202.55M and its 3Y-monthly beta is at 2.27. It has posted earnings per share of -$0.39 in the same period. It has Quick Ratio of 4.64 while making debt-to-equity ratio of 0.03. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for SLS, volatility over the week remained 9.35% while standing at 7.75% over the month.
Stock’s fiscal year EPS is expected to rise by 36.67% while it is estimated to decrease by -20.00% in next year. EPS is likely to shrink at an annualized rate of 33.56% for next 5-years, compared to annual growth of 45.94% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Cantor Fitzgerald on July 21, 2021 offering an Overweight rating for the stock and assigned a target price of $18 to it. On April 02, 2018, H.C. Wainwright Initiated their recommendations, while on March 19, 2018, Maxim Group Upgrade their ratings for the stock with a price target of $13.
